tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Liver Diseases D008107 31 associated lipids
Cardiomegaly D006332 31 associated lipids
Stroke D020521 32 associated lipids
Diarrhea D003967 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Uremia D014511 33 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Burns D002056 34 associated lipids
Cataract D002386 34 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Glomerulonephritis D005921 35 associated lipids
Fever D005334 35 associated lipids
Heart Failure D006333 36 associated lipids
Nervous System Diseases D009422 37 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hara Y et al. Unresponsiveness to rat cardiac allografts induced by intrathymic injection of donor bone marrow cells and short course of immunosuppression. 1994 Transplant. Proc. pmid:7527955
Guy S et al. Immunosuppression conversion for relief of side effects. 1994 Transplant. Proc. pmid:7527956
Starzl TE FK 506 versus cyclosporine. 1993 Transplant. Proc. pmid:7679820
Nakajima K et al. Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. 1993 Transplant. Proc. pmid:7679821
Hu RH et al. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. 2000 Transplant. Proc. pmid:11119894
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin. 1994 Transplant. Proc. pmid:7513476
Yashima J et al. Successful conversion from tacrolimus to cyclosporine after kidney transplantation. 2000 Transplant. Proc. pmid:11119895
Nomoto S et al. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. 1994 Transplant. Proc. pmid:7513477
Stringa P et al. Pretreatment Combination Reduces Remote Organ Damage Secondary to Intestinal Reperfusion Injury in Mice: Follow-up Study. Transplant. Proc. pmid:26915870
Pham SM et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. 1996 Transplant. Proc. pmid:8623208
Satomura K et al. Pharmacokinetics of FK 506 in living-related liver transplantation. 1996 Transplant. Proc. pmid:8623209
Machado PG et al. Use of reduced dose of OKT3 (2.5 mg) after renal transplantation. 2002 Transplant. Proc. pmid:11959207
Chakkera HA et al. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375287
Tian Ch et al. B- and T-lymphocyte attenuator/herpes virus entry mediator as early indicators for acute rejection following kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375291
Jain A et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. 1998 Transplant. Proc. pmid:9636567
Matevossian E et al. Liver transplantation in the rat: single-center experience with technique, long-term survival, and functional and histologic findings. 2009 Jul-Aug Transplant. Proc. pmid:19715990
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Pichard L et al. Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. 1991 Transplant. Proc. pmid:1721279
Viganó J et al. Incidence of graft rejection in small bowel transplanted pigs after immunosuppression withdrawal. 2006 Jul-Aug Transplant. Proc. pmid:16908291
Higuchi K et al. FK506 induces the atrophy of enteric ganglia in small bowel transplantation, which can be prevented by the neuropeptide bombesin. 2006 Jul-Aug Transplant. Proc. pmid:16908293
McCauley J et al. FK 506 in the management of nephrotic syndrome after renal transplantation. 1993 Transplant. Proc. pmid:7680154
Sekido H et al. Successful conversion from cyclosporine to tacrolimus for immunosuppression. 2000 Transplant. Proc. pmid:11120096
Friemann S et al. Conversion to tacrolimus in hyperlipidemic patients. 1999 Transplant. Proc. pmid:10576042
Yilmaz A et al. Severe angioedema caused by banana allergy under tacrolimus immunosuppression. 2005 Transplant. Proc. pmid:16387091
Lai WJ et al. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? 2004 Transplant. Proc. pmid:15518744
Kohnle M et al. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia. 1999 Transplant. Proc. pmid:10576043
Barten MJ et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. 2005 Transplant. Proc. pmid:16387162
Chueh SC et al. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. 2004 Transplant. Proc. pmid:15518745
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
Meçule A et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. 2010 Transplant. Proc. pmid:20534290
Peddi VR et al. Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9636626
Burke GW et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. 1998 Transplant. Proc. pmid:9636627
Chen JS et al. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. 2009 Transplant. Proc. pmid:19545678
Cabello M et al. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. 2010 Transplant. Proc. pmid:20970603
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Andersson J et al. The effects of FK 506 on cytokine production are dependent on the mode of cell activation. 1991 Transplant. Proc. pmid:1721311
Mueller AR et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. 1997 Transplant. Proc. pmid:9365585
Li D et al. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. 2006 Transplant. Proc. pmid:17112846
Platz KP et al. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. 1997 Transplant. Proc. pmid:9365598
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Demetris AJ et al. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. 1993 Transplant. Proc. pmid:7505503
Klintmalm GB et al. Rejection: FK 506 for rescue or maintenance. 1993 Transplant. Proc. pmid:7682356
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Tullius SG et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. 2003 Transplant. Proc. pmid:14529854
Todo S et al. Intestinal transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7518136
Manu MA et al. Tacrolimus rescue for resistant rejection, chronic rejection, and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. 1999 Transplant. Proc. pmid:10578313
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Lang T et al. Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. 1995 Transplant. Proc. pmid:7533367
Ito Y et al. Inhibition of epithelial replacement by nonspecific immunosuppressants accelerates rat orthotopic tracheal allograft rejection. 2002 Transplant. Proc. pmid:12176430
Tzakis AG et al. FK 506 versus cyclosporine in pediatric liver transplantation. 1991 Transplant. Proc. pmid:1721343
Ping X et al. Antigen sampling on the Peyer's patches in a murine small bowel transplantation model. 2010 Transplant. Proc. pmid:21094860
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Signorell J et al. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. 2010 Transplant. Proc. pmid:21094874
Marin M et al. Factors influencing the onset of diabetes mellitus after kidney transplantation: a single French center experience. 2005 Transplant. Proc. pmid:15919484
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Altaca G et al. Effect of low-dose calcineurin inhibitors on acute rejection and graft survival. 2002 Transplant. Proc. pmid:12270320
Tanabe K et al. Outcome of kidney transplantation from non-heart-beating donors followed by tacrolimus immunosuppression in japan. 2002 Transplant. Proc. pmid:12176493
Squifflet JP et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. 2002 Transplant. Proc. pmid:12176495
Cotovio P et al. New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes. 2013 Transplant. Proc. pmid:23622631
Ko WJ et al. Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506. 1998 Transplant. Proc. pmid:9838474
Shapiro R Tacrolimus (FK-506) in kidney transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123077
Borda B et al. Functional and histopathologic changes in renal transplant patients with new-onset diabetes and dyslipidemia. 2011 Transplant. Proc. pmid:21620104
Morris SM et al. Disruption of renal function and gene expression by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721375
Reggiani P et al. Oral administration of FK 506 in a swine model of liver-small bowel allotransplantation. 1996 Transplant. Proc. pmid:8907965
Jiang H et al. FK 506 and deoxyspergualin: additive immunosuppressive effect on rat cardiac allograft rejection in vivo and mitogen-stimulated human lymphocyte responses in vitro. 1994 Transplant. Proc. pmid:7520631
Wada Y et al. Expression of the transcriptional factor egr-1/BTEB2 in cardiac xenograft vascular remodeling. 2000 Transplant. Proc. pmid:10936371
Beaunoyer M et al. Low-dose tacrolimus, trough-monitored mycophenolate mofetil, and planned steroid withdrawal for cadaveric kidney transplantation: a single center experience. 2002 Transplant. Proc. pmid:12176540
Limsrichamrern S et al. Correlation of Hematocrit and Tacrolimus Level in Liver Transplant Recipients. 2016 Transplant. Proc. pmid:27320581
McAlister VC et al. Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. 1999 Feb-Mar Transplant. Proc. pmid:10083495
Lee S et al. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. 2010 Transplant. Proc. pmid:20430174
Klupp J et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083497
Kim JM et al. Preemptive therapy in adult liver transplant recipients in CMV-endemic area. 2010 Transplant. Proc. pmid:20430182
Ju MK et al. A 6-month, open-label, multicenter clinical study in Korean de novo renal transplant patients evaluating the efficacy, safety, and tolerance of myfortic concomitantly used with tacrolimus. 2012 Transplant. Proc. pmid:22310600
Basadonna GP et al. Pancreas after kidney transplantation: HLA mismatch does not preclude success. 1997 Feb-Mar Transplant. Proc. pmid:9123470
Alessiani M et al. Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression. 1997 Feb-Mar Transplant. Proc. pmid:9123483
Kato Y et al. Epidermal growth factor enhances the intestinal adaptation of small bowel allografts in the postoperative period. 2000 Transplant. Proc. pmid:10995935
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation in rats. 1991 Transplant. Proc. pmid:1721413
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Degawa H et al. Blocking of ICAM-1 and LFA-1 in rat liver transplantation. 1996 Transplant. Proc. pmid:8658695
Rigotti P et al. Antilymphocyte induction is no longer necessary in simultaneous pancreas and kidney transplantation. 2002 Transplant. Proc. pmid:12176623
Salazar A et al. Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: effect on renal function. 2001 Feb-Mar Transplant. Proc. pmid:11267181
Yoshimura R et al. Hepatocyte growth factor: a sensitive indicator for CsA-induced nephropathy. 1998 Transplant. Proc. pmid:9723373
Veroux M et al. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. 2006 Transplant. Proc. pmid:16757256
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
Winkler M et al. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. 1993 Transplant. Proc. pmid:7689277
Wang CH et al. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. 2004 Transplant. Proc. pmid:15561257
Heffron TG et al. Daclizumab induction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267408
Rabkin JM et al. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267411
Nakai T et al. Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. 1999 Transplant. Proc. pmid:10500761
Krüger B et al. Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. 1998 Transplant. Proc. pmid:9636399
McAlister VC Liposomal tacrolimus: drug migration within blood compartments. 1998 Transplant. Proc. pmid:9636404
Rong G et al. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. 2010 Transplant. Proc. pmid:21094796
Fu Q et al. Risk Factors for Acute Rejection After Deceased Donor Kidney Transplantation in China. 2018 Transplant. Proc. pmid:30316380
Konno O et al. Early Outcomes of Living-Donor Kidney Transplantation With Immunosuppression Therapy Induction With Tacrolimus Extended-Release: A Comparison With Cyclosporine. 2018 Transplant. Proc. pmid:30316378
Barak S et al. Alveolar bone height in patients after liver transplantation. 2000 Transplant. Proc. pmid:10856558
Suarez Benjumea A et al. Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to Eradication. 2016 Transplant. Proc. pmid:27932111
Rathi M et al. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study. 2015 Transplant. Proc. pmid:26036543
Shapiro R The development of tacrolimus in renal transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750356
Morris-Stiff G et al. Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report. 1998 Transplant. Proc. pmid:9636506